COEP Profile
Coeptis Therapeutics Holdings, Inc., headquartered in Wexford, Pennsylvania, is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for cancer treatment. The company focuses on both generic and branded pharmaceutical products as well as advanced cell therapy platforms. Its diverse portfolio targets a range of oncological conditions through cutting-edge technologies and strategic collaborations.
Among Coeptis' notable products is CD38-GEAR-NK, a novel cell therapy designed to target CD38-positive cancers. This therapy is aimed at treating challenging malignancies such as multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia. Additionally, the company has developed SNAP-CAR, a versatile CAR T cell therapy platform that utilizes tagged, tumor-specific antibodies to potentially address various tumor types, including both hematological malignancies and solid tumors.
Coeptis also offers CD38-Diagnostic, an in vitro diagnostic tool that helps assess whether cancer patients are suitable candidates for anti-CD38 monoclonal antibody therapy. This diagnostic tool supports personalized treatment approaches by identifying patients who may benefit from targeted therapies.
The company is actively engaged in collaborative efforts to enhance its therapeutic offerings. It has partnered with Statera BioPharma to develop and commercialize STAT-201, a treatment for Crohn's disease. Additionally, Coeptis is working with Vici Health Sciences, LLC on the co-development and shared ownership of CPT60621, a therapeutic candidate for Parkinson's disease. Founded in 2017, Coeptis Therapeutics Holdings, Inc. continues to advance its mission to deliver transformative treatments for patients with cancer and other serious conditions.
|
